Remdesivir in Severe Cases of COVID-19 Infection

被引:0
|
作者
Boretti, Alberto [1 ]
机构
[1] Independent Sci, Wellington, New Zealand
关键词
Remdesivir; COVID-19; ARDS; severe ARDS; ICU care; virology;
D O I
10.2174/0122133372290992240409084133
中图分类号
O64 [物理化学(理论化学)、化学物理学];
学科分类号
070304 ; 081704 ;
摘要
Background Assessing the efficacy of remdesivir for COVID-19 infection holds historical significance. Understanding its effectiveness from previous pandemic instances can enable us to gain insights into its efficacy, informing our strategies for responding to future outbreaks or variants.Objective Gaining an insight into the historical efficacy of remdesivir can offer valuable data for evaluating the advancement of COVID-19 treatments and the development of medical expertise in handling the disease.Methods The historical data regarding the effectiveness of remdesivir can enrich the pool of knowledge and evidence accessible for public health planning and decision-making. Understanding whether remdesivir was efficacious in previous instances may aid in comprehending its real-world impact on patient outcomes at those times. Such insights are crucial for evaluating treatment efficacy and refining strategies based on past experiences.Results In the late treatment of severe COVID-19 cases, which are particularly challenging, remdesivir has demonstrated a 6% improvement.Conclusion The 6% enhanced effect of remdesivir is not substantial, considering that it is an unweighted average of works with varying degrees of importance and reliability. Additionally, there are instances where conflicts of interest may have impacted the results. It is also possible that the observed improvement could be attributed to better patient care in certain environments.
引用
收藏
页码:273 / 278
页数:6
相关论文
共 50 条
  • [21] Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
    Goldman, Jason D.
    Lye, David C. B.
    Hui, David S.
    Marks, Kristen M.
    Bruno, Raffaele
    Montejano, Rocio
    Spinner, Christoph D.
    Galli, Massimo
    Ahn, Mi-Young
    Nahass, Ronald G.
    Chen, Yao-Shen
    SenGupta, Devi
    Hyland, Robert H.
    Osinusi, Anu O.
    Cao, Huyen
    Blair, Christiana
    Wei, Xuelian
    Gaggar, Anuj
    Brainard, Diana M.
    Towner, William J.
    Munoz, Jose
    Mullane, Kathleen M.
    Marty, Francisco M.
    Tashima, Karen T.
    Diaz, George
    Subramanian, Aruna
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (19): : 1827 - 1837
  • [22] A Retrospective Study of Dexamethasone, Remdesivir, and Baricitinib in Severe COVID-19
    Ngo, Dallis Q.
    Hamid, Kewan
    Rana, Haris
    Cardinale, Maria
    Frenia, Douglas
    Ghani, Nabil
    Redel, Henry
    [J]. CANADIAN JOURNAL OF INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY, 2022, 2022
  • [23] Severe COVID-19 Pneumonia in an Unvaccinated Female Treated With Remdesivir
    Ortega, Kaylee
    George, Andrew
    DeGeorge, Charlotte R.
    Stead, Thor S.
    Mangal, Rohan
    DeLosSantos, Jesse
    Ganti, Latha
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (10)
  • [24] Outpatient Remdesivir to Prevent Progression to Severe Covid-19 REPLY
    Gottlieb, Robert L.
    Juneja, Kavita
    Hill, Joshua A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022,
  • [25] Outpatient Remdesivir to Prevent Progression to Severe Covid-19 REPLY
    Gottlieb, Robert L.
    Juneja, Kavita
    Hill, Joshua A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (11): : 1094 - 1094
  • [27] Remdesivir - Current evidence & perspective in management of COVID-19 infection
    Bajpai, Jyoti
    Kant, Surya
    Pradhan, Akshyaya
    Verma, Ajay K.
    [J]. JOURNAL OF FAMILY MEDICINE AND PRIMARY CARE, 2021, 10 (05) : 1808 - 1813
  • [28] Remdesivir and COVID-19 infection, therapeutic benefits or unnecessary risks?
    Vitiello, Antonio
    Ferrara, Francesco
    La Porta, Raffaele
    [J]. IRISH JOURNAL OF MEDICAL SCIENCE, 2021, 190 (04) : 1637 - 1638
  • [29] Remdesivir and COVID-19 infection, therapeutic benefits or unnecessary risks?
    Antonio Vitiello
    Francesco Ferrara
    Raffaele La Porta
    [J]. Irish Journal of Medical Science (1971 -), 2021, 190 : 1637 - 1638
  • [30] Perspectives of association Baricitinib/Remdesivir for adults with Covid-19 infection
    Vitiello, Antonio
    Ferrara, Francesco
    [J]. MOLECULAR BIOLOGY REPORTS, 2022, 49 (01) : 827 - 831